ClinicalTrials.Veeva

Menu
D

Docrates Syopasairaala | Helsinki, Finland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Docetaxel
Bemarituzumab
Enzalutamide
510

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 3 total trials

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Enrolling
Solid Tumors
Drug: Bemarituzumab

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Active, not recruiting
Nonmetastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Drug: Placebo
Drug: Enzalutamide

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Active, not recruiting
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Drug: AMG 510
Drug: Docetaxel

Trial sponsors

Amgen logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems